DOCSLIB.ORG

Introduction Results Methods

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction Results Methods Dysregulated epigenome in perinatally HIV-infected children on antiretrovirals 1 1 2 2 1 Stephanie Shiau, MPH Stephanie Shiau , Stephen M. Arpadi , Renate Strehlau , Avy Violari , Shuang Wang , Columbia University 2 1 2 1 1 G.H. Sergievsky Center Faeezah Patel , Marc Foca , Ashraf Coovadia , Elaine J. Abrams , Louise Kuhn , 622 W 168th Street PH 19-110 New York, NY 10032 CHANGES Study Team [email protected] 1Columbia University, New York, NY, USA, 2University of the Witwatersrand, Johannesburg, South Africa 851 Pre-Processing and Normalization Table 3. Characteristics of 119 HIV-infected and Gene Function Introduction 60 HIV-uninfected children ages 5-9 years Pre-processing and normalization was performed with the Comparing HIV-infected and HIV-uninfected children, functional Early initiation of antiretroviral therapy (ART) has improved R/Bioconductor RnBeads package (2). HIV+ HIV- analysis identified 33 enriched GO terms for the 83 gene regions and survival for perinatally HIV-infected children. Characteristic (N = 119) (N = 60) 68 enriched GO terms for the 184 promoter regions. The top 15 GO A total of 85049 probes were removed in pre-processing (Table 1), Site, N (%) terms for both are presented in Table 5. A major focus is now on the increased risk of complications leaving a total of 400528 sites suitable for analysis. ESRU 62 (52.1) 20 (33.3) related to long-term HIV infection and its treatment, including PHRU 57 (47.9) 40 (66.7) Table 5. Top 15 enriched gene ontology terms identified in cardiovascular disease, central nervous system abnormalities, and Background subtraction was performed using methylumi (3) and the Male, % 46 50 functional analysis using DAVID musculoskeletal complications. BMIQ method was used to normalize the values (4). Age, Mean (SD) 6.4 ± 1.4 6.4 ± 1.4 Primary Caregiver Mother, N (%) 109 (90.8) 57 (95.0) GO Terms (Genes) Count GO Terms (Promoter Regions) Count Table 1. Detailed on sites filtered in pre-processing immune response 11 second-messenger-mediated signaling 10 DNA methylation is an important epigenetic marker and widely Lives in house, N (%) 74 (62.2) 38 (63.3) positive regulation of cell communication 8 behavior 13 studied in the context of biological processes and diseases. Total sites 485577 Someone in home smokes, N (%) 41 (34.5) 22 (36.7) G-protein coupled receptor protein regulation of adenylate cyclase activity 6 signaling pathway 13 Studying these epigenetic markers may identify novel biological SNP-enriched probes removed 47555 Highest caregiver grade, N (%) regulation of cyclase activity 6 cell surface receptor linked signal regulation of lyase activity 6 No School 0 (0.0) 1 (1.7) transduction 17 pathways affected by HIV and ART. Cross-reactive probes removed 25673 regulation of cAMP biosynthetic process 6 1-11 66 (55.5) 36 (60.0) positive regulation of signal transduction 7 Probes with detection p-value ≥ 0.05 removed 1855 regulation of cAMP metabolic process 6 12 (finished high school) 53 (44.5) 23 (38.3) immune system process 12 Context-specific probes removed 65 regulation of cyclic nucleotide biosynthetic It plausible that the epigenome is affected, as perinatal acquisition taxis 5 Probes on sex chromosomes removed 9901 Caregiver has paid job, N (%) 52 (43.7) 22 (36.7) process 6 of HIV and early initiation of ART takes place in a critical chemotaxis 5 regulation of nucleotide biosynthetic process 6 developmental period. Studies of in utero tobacco exposure and Total probes removed 85049 locomotory behavior 6 cell surface receptor linked signal transduction 30 Characteristics between HIV-infected and HIV-uninfected children prenatal exposure to famine have detected epigenetic changes. Total sites remaining for analysis 400528 defense response 8 G-protein coupled receptor protein signaling were similar when stratified by sex. inflammatory response 6 pathway 21 Analysis regulation of cell communication 10 regulation of cyclic nucleotide metabolic process 6 The aim of this study is to investigate the cumulative impact of positive regulation of multicellular G-protein signaling, coupled to cyclic nucleotide Differentially Methylated Loci (DML) organismal process 5 second messenger 6 perinatal HIV infection and ART on the epigenetic profile of Analysis was performed using the RnBeads package (2). regulation of signal transduction 9 regulation of hydrolase activity 10 school-aged children and identify affected biological pathways by signal transduction 18 regulation of nucleotide metabolic process 6 conducting an epigenome-wide association study. Differentially methylated loci (DML) meeting an adjusted FDR p- Manhattan plots of the DMLs are shown in Figure 1. value <0.05 were identified using limma (5). Manhattan plots were For boys, GO terms for genes and promoters were similar to above. generated to provide a visual representation of the DML. 161241 DMLs were identified for HIV-infected vs. HIV-uninfected; For girls, although GO terms for promoters were similar to above, 100216 for boys and 3091 for girls. DMRs mapped to only 3 named genes with no GO terms were Pre-defined regions (Table 2) were assigned a rank (lower rank = included EGFLAM-AS1 (chr5), LINC00615 (chr12), MIR1914 (chr20). Methods more evidence for differential methylation) based on these criteria: Figure 1. Manhattan plots Table 6. Exploratory selection of genes with biological function Study Sample 1. Mean difference in mean methylation potentially relevant to HIV infection and its complications 2. Log2 of the mean quotient in mean methylation HIV+ vs. HIV- Boys HIV+ vs. Boys HIV- Girls HIV+ vs. Girls HIV- The study included 120 HIV-infected and 60 frequency age-matched 3. Combined adjusted FDR p-value <0.05 from all sites in the region Category Genes (Chromosome) HIV-uninfected children aged 4-9 years participating in a Table 2. Pre-defined regions Immune response; FCER1G (chr1), LURAP1 (chr1), ICOS (chr2), IL1B (chr2), longitudinal observational study (CHANGES) at two sites (Empilweni TRAT1 (chr3), NKAPL (chr6), CD163 (chr12), CLEC4A inflammation; Services and Research Unit and Perinatal HIV Research Unit) in Region Maximum Definition (chr12), CLEC4E (chr12), ENDOU (chr12), CEBPE (chr14), cytokines Johannesburg, South Africa. Genes 27862 Whole locus from transcription start site to end CCL16 (chr17), CCL2 (chr17), CCL23 (chr17), CCL8 (chr17) site Fat metabolism; AGPAT2 (chr9); LIPF (chr10), SLCO1B1 (chr12) Promoters 28116 Span 1500 bases upstream and 500 bases Lipids; Lipodystrophy downstream of transcription start sites of genes Bone: CTSK (chr1), DKK4 (chr8), LNX2 (chr13) Musculoskeletal Muscle: MYF5 (chr12) We assessed differentially methylated regions (DMRs) that met a HTR2B (chr2), TACR3 (chr4), TBATA (chr10), MTNR1B Central nervous rank cut-off selected by the software. (chr11), P2RX2 (chr 12), SKOR2 (chr18), MC5R (chr18), Differentially Methylated Regions (DMRs) system CBLN4 (chr20) HIV-infected children were initiated on ART ≤24 months of age, Functional analysis of DMRs mapping to genes and promoter regions Special senses Vision: MTNR1B (chr11), PDE6H (chr12); HSPB6 (chr19) consistently on treatment, and suppressed (HIV RNA <400 was explored using the Database for Annotation, Visualization, and The number of DMRs at genes and promoters meeting the rank cut- (vision and hearing) Hearing: OR8B12 (chr11), OR8B8 (chr11), P2RX2 (chr 12) copies/mL) on a LPV/r-based regimen. Integrated Discovery (DAVID) (6). The software produced lists of off and with gene ontology information for all children and stratified enriched gene ontology (GO) terms. In an exploratory analysis, we by sex was determined (Table 4). At the enrollment visit, detailed demographic and clinical data was selected genes with biological functions relevant to HIV infection collected. Bloods were drawn and processed for storage. CD4 and and its complications and placed them in categories. Table 4. Differentially methylated regions meeting rank cut-off HIV-1 RNA levels were measured for HIV-infected children. The analysis was repeated stratified by sex. HIV+ HIV+ Boys HIV+ Girls Conclusions Infinium HumanMethylation450 BeadChip Region Type Group vs. vs. vs. HIV- HIV- Boys HIV- Girls We detected a dysregulated epigenome in school-aged children Extraction of genomic DNA (50ng/µl) from total WBC was Results Meeting rank cut-off 202 81 13 perinatally infected with HIV and initiated on ART <2 years of age. performed via picogreen quantitation (Lifetechnologies) by Genes Has gene name 106 42 3 Biomarkers Shared Resource at Columbia University. One sample did Has gene ontology info 83 32 0 Characteristics Functional analysis identified genes potentially affected by HIV not meet adequate DNA extraction leaving 119 samples for analysis. Meeting rank cut-off 352 125 256 and ART. A sub-set of these genes may be relevant to HIV-related Characteristics of 119 HIV-infected children and 60 HIV-uninfected Promoters Has gene name 232 80 167 complications. DNA methylation analysis was performed at Roswell Park Cancer children included in this analysis are shown in Table 3. Has gene ontology info 184 61 127 Institute (Buffalo, NY) Core Facility with the Infinium HumanMethylation450 BeadChip Kit (Illumina, Inc.). Mean age was similar between HIV-infected and uninfected children (6.4 ± 1.4 vs. 6.4 ± 1.4, NS), as was the proportion of males (46.2 vs The OSAT tool was used to allocate randomly assign samples (by 50.0%, NS). group, sex, and age) to specific positions to minimize the impact of References Acknowledgements All HIV-infected children were on LPV/r-based ART and had a viral (1) Yan et al. BMC Genomics 2012. (2) Assenov et al. Nat Methods 2014; “batch” effects across chips (1). This study was supported by funding from the National Institute (3) Davis et al. R: methylumi 2015; (4) Teschendorff et al. Bioinformatics 2013; load <400 copies/ml. Mean CD4% was 33.4 ± 6.4. Mean duration on of Child Health & Human Development (HD 073977, HD 073952). Raw intensity data (IDAT) files were obtained for analysis. treatment was 5.7 ± 1.4 years. (5) Ritchie et al. Nuc Acid Research 2015; (6) Huang et al.
Load more

Recommended publications
  • The Plasma Peptides of Alzheimer's Disease
    Florentinus‑Mefailoski et al. Clin Proteom (2021) 18:17 https://doi.org/10.1186/s12014‑021‑09320‑2 Clinical Proteomics RESEARCH Open Access The plasma peptides of Alzheimer’s disease Angelique Florentinus‑Mefailoski1, Peter Bowden1, Philip Scheltens2, Joep Killestein3, Charlotte Teunissen4 and John G. Marshall1,5* Abstract Background: A practical strategy to discover proteins specifc to Alzheimer’s dementia (AD) may be to compare the plasma peptides and proteins from patients with dementia to normal controls and patients with neurological condi‑ tions like multiple sclerosis or other diseases. The aim was a proof of principle for a method to discover proteins and/ or peptides of plasma that show greater observation frequency and/or precursor intensity in AD. The endogenous tryptic peptides of Alzheimer’s were compared to normals, multiple sclerosis, ovarian cancer, breast cancer, female normal, sepsis, ICU Control, heart attack, along with their institution‑matched controls, and normal samples collected directly onto ice. Methods: Endogenous tryptic peptides were extracted from blinded, individual AD and control EDTA plasma sam‑ ples in a step gradient of acetonitrile for random and independent sampling by LC–ESI–MS/MS with a set of robust and sensitive linear quadrupole ion traps. The MS/MS spectra were ft to fully tryptic peptides within proteins identi‑ fed using the X!TANDEM algorithm. Observation frequency of the identifed proteins was counted using SEQUEST algorithm. The proteins with apparently increased observation frequency in AD versus AD Control were revealed graphically and subsequently tested by Chi Square analysis. The proteins specifc to AD plasma by Chi Square with FDR correction were analyzed by the STRING algorithm.
    [Show full text]
  • Genome-Wide Transcriptome Analysis of Laminar Tissue During the Early Stages of Experimentally Induced Equine Laminitis
    GENOME-WIDE TRANSCRIPTOME ANALYSIS OF LAMINAR TISSUE DURING THE EARLY STAGES OF EXPERIMENTALLY INDUCED EQUINE LAMINITIS A Dissertation by JIXIN WANG Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 2010 Major Subject: Biomedical Sciences GENOME-WIDE TRANSCRIPTOME ANALYSIS OF LAMINAR TISSUE DURING THE EARLY STAGES OF EXPERIMENTALLY INDUCED EQUINE LAMINITIS A Dissertation by JIXIN WANG Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Approved by: Chair of Committee, Bhanu P. Chowdhary Committee Members, Terje Raudsepp Paul B. Samollow Loren C. Skow Penny K. Riggs Head of Department, Evelyn Tiffany-Castiglioni December 2010 Major Subject: Biomedical Sciences iii ABSTRACT Genome-wide Transcriptome Analysis of Laminar Tissue During the Early Stages of Experimentally Induced Equine Laminitis. (December 2010) Jixin Wang, B.S., Tarim University of Agricultural Reclamation; M.S., South China Agricultural University; M.S., Texas A&M University Chair of Advisory Committee: Dr. Bhanu P. Chowdhary Equine laminitis is a debilitating disease that causes extreme sufferring in afflicted horses and often results in a lifetime of chronic pain. The exact sequence of pathophysiological events culminating in laminitis has not yet been characterized, and this is reflected in the lack of any consistently effective therapeutic strategy. For these reasons, we used a newly developed 21,000 element equine-specific whole-genome oligoarray to perform transcriptomic analysis on laminar tissue from horses with experimentally induced models of laminitis: carbohydrate overload (CHO), hyperinsulinaemia (HI), and oligofructose (OF).
    [Show full text]
  • WO 2019/068007 Al Figure 2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/068007 Al 04 April 2019 (04.04.2019) W 1P O PCT (51) International Patent Classification: (72) Inventors; and C12N 15/10 (2006.01) C07K 16/28 (2006.01) (71) Applicants: GROSS, Gideon [EVIL]; IE-1-5 Address C12N 5/10 (2006.0 1) C12Q 1/6809 (20 18.0 1) M.P. Korazim, 1292200 Moshav Almagor (IL). GIBSON, C07K 14/705 (2006.01) A61P 35/00 (2006.01) Will [US/US]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., C07K 14/725 (2006.01) P.O. Box 4044, 7403635 Ness Ziona (TL). DAHARY, Dvir [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (21) International Application Number: Box 4044, 7403635 Ness Ziona (IL). BEIMAN, Merav PCT/US2018/053583 [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (22) International Filing Date: Box 4044, 7403635 Ness Ziona (E.). 28 September 2018 (28.09.2018) (74) Agent: MACDOUGALL, Christina, A. et al; Morgan, (25) Filing Language: English Lewis & Bockius LLP, One Market, Spear Tower, SanFran- cisco, CA 94105 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/564,454 28 September 2017 (28.09.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/649,429 28 March 2018 (28.03.2018) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicant: IMMP ACT-BIO LTD.
    [Show full text]
  • Sean Raspet – Molecules
    1. Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Molecular weight: 240.39 g/mol Volume (cubic Angstroems): 258.88 Atoms number (non-hydrogen): 17 miLogP: 4.43 Structure: Biological Properties: Predicted Druglikenessi: GPCR ligand -0.23 Ion channel modulator -0.03 Kinase inhibitor -0.6 Nuclear receptor ligand 0.15 Protease inhibitor -0.28 Enzyme inhibitor 0.15 Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Predicted Olfactory Receptor Activityii: OR2L13 83.715% OR1G1 82.761% OR10J5 80.569% OR2W1 78.180% OR7A2 77.696% 2. Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Molecular weight: 239.36 Volume (cubic Angstroems): 252.83 Atoms number (non-hydrogen): 17 miLogP: 4.33 Structure: Biological Properties: Predicted Druglikeness: GPCR ligand -0.6 Ion channel modulator -0.41 Kinase inhibitor -0.93 Nuclear receptor ligand -0.17 Protease inhibitor -0.39 Enzyme inhibitor 0.01 Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Predicted Olfactory Receptor Activity: OR52D1 71.900% OR1G1 70.394% 0R52I2 70.392% OR52I1 70.390% OR2Y1 70.378% 3. Commercial name: Hyperflor© IUPAC Name: 2-benzyl-1,3-dioxan-5-one SMILES: O=C1COC(CC2=CC=CC=C2)OC1 Molecular weight: 192.21 g/mol Volume
    [Show full text]
  • Preview of “Supplement Table S4.Xls”
    Annotations for all recurrently lost regions cytoband 1p36.12 3p14.2 3q13.13 q value 0,01352 0,1513 0,085307 residual q value 0,01352 0,1513 0,085307 wide peak boundaries chr1:23457835-23714048 chr3:60396160-60637030 chr3:110456383-110657226 genes in wide peak E2F2 FHIT DPPA4 ID3 DPPA2 TCEA3 DDEFL1 TBC1D19 PI4K2B STIM2 GBA3 KCNIP4 DKFZp761B107 C4orf28 GPR125 FLJ45721 hsa-mir-218-1 CXCL3 GRSF1 HNRPD HTN1 HTN3 IBSP IGFBP7 IGJ IL8 CXCL10 KDR CXCL9 AFF1 MUC7 NKX6-1 PF4 PF4V1 PKD2 POLR2B PPEF2 PPAT PPBP PRKG2 MAPK10 PTPN13 REST CXCL6 CXCL11 CXCL5 SPINK2 SPP1 SRP72 STATH SULT1E1 UGT2B4 UGT2B7 UGT2B10 UGT2B15 UGT2B17 SPARCL1 VDP SLC4A4 HERC3 GENX-3414 CDKL2 TMPRSS11D ABCG2 ADAMTS3 CLOCK CEP135 G3BP2 HNRPDL ENAM FAM13A1 CXCL13 PAICS UGT2B11 HPSE NMU SMR3B NPFFR2 UGT2A1 CCNI hsa-mir-491 hsa-mir-31 4p15.32 4q13.1 4q13.1 (continued) 6q14.1 0,14888 0,17878 0,093693 0,14888 0,17878 0,093693 chr4:17969802-29966659 chr4:55756035-90966136 chr6:76830186-107898353 CCKAR AFM SEC31A AIM1 DHX15 AFP RUFY3 BCKDHB RBPSUH ALB WDFY3 PRDM1 SOD3 AMBN LPHN3 CCNC SLIT2 ANXA3 DKFZP564O0823 CGA SLC34A2 AREG RCHY1 CNR1 PPARGC1A ART3 ANKRD17 EPHA7 KIAA0746 BMP3 BRDG1 GABRR1 ANAPC4 BTC SMR3A GABRR2 SLA/LP CCNG2 ASAHL GRIK2 LGI2 SCARB2 COQ2 HTR1B TBC1D19 CDS1 SULT1B1 HTR1E PI4K2B CENPC1 TMPRSS11E IMPG1 STIM2 CSN1S1 MRPS18C ME1 GBA3 CSN2 COPS4 NT5E KCNIP4 CSN3 HSD17B11 PGM3 DKFZp761B107 DCK HERC5 POU3F2 C4orf28 DMP1 PLAC8 PREP GPR125 DSPP NUDT9 SIM1 FLJ45721 EPHA5 NUP54 ELOVL4 hsa-mir-218-1 EREG UGT2B28 MAP3K7 FGF5 ODAM TPBG GC HERC6 TTK GK2 SDAD1 RNGTT GNRHR UBE1L2 TBX18
    [Show full text]
  • A Comprehensive Analysis of Differentially Expressed Genes and Pathways in Abdominal Aortic Aneurysm
    MOLECULAR MEDICINE REPORTS 12: 2707-2714, 2015 A comprehensive analysis of differentially expressed genes and pathways in abdominal aortic aneurysm KAI YUAN, WEI LIANG and JIWEI ZHANG Department of Vascular Surgery, Renji Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai 200127, P.R. China Received May 29, 2014; Accepted March 3, 2015 DOI: 10.3892/mmr.2015.3709 Abstract. The current study aimed to investigate the molecular inal aorta exceeding the normal aortic diameter by >50% (1). mechanism underlying abdominal aortic aneurysm (AAA) The most severe complication of AAA is AAA rupture, via various bioinformatics techniques. Gene expression which is the tenth primary cause of mortality for American profiling analysis of differentially expressed genes (DEGs) Caucasian males between 65-74 years old (2). As AAA rupture between AAA samples and normal controls was conducted. is fatal within minutes, in the majority of cases, the patients do The Database for Annotation, Visualization and Integrated not reach hospital in time to receive treatment. Therefore, the Discovery tool was utilized to perform Gene ontology (GO) mortality rate of AAA rupture is ~90% (3). and Kyoto Encyclopedia of Genes and Genomes analyses for Thus, there is an urgent requirement for the development DEGs and clusters from the protein-protein interaction (PPI) of effective therapies for AAA, and elucidating the etiology network, which was constructed using the Search Tool for the of AAA is important in this development. Chronic tobacco Retrieval of Interacting Genes. In addition, important tran- smoking has been identified as the most important risk factor scription factors (TFs) that regulated DEGs were investigated.
    [Show full text]
  • The Hypothalamus As a Hub for SARS-Cov-2 Brain Infection and Pathogenesis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis Sreekala Nampoothiri1,2#, Florent Sauve1,2#, Gaëtan Ternier1,2ƒ, Daniela Fernandois1,2 ƒ, Caio Coelho1,2, Monica ImBernon1,2, Eleonora Deligia1,2, Romain PerBet1, Vincent Florent1,2,3, Marc Baroncini1,2, Florence Pasquier1,4, François Trottein5, Claude-Alain Maurage1,2, Virginie Mattot1,2‡, Paolo GiacoBini1,2‡, S. Rasika1,2‡*, Vincent Prevot1,2‡* 1 Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, DistAlz, UMR-S 1172, Lille, France 2 LaBoratorY of Development and PlasticitY of the Neuroendocrine Brain, FHU 1000 daYs for health, EGID, School of Medicine, Lille, France 3 Nutrition, Arras General Hospital, Arras, France 4 Centre mémoire ressources et recherche, CHU Lille, LiCEND, Lille, France 5 Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and ImmunitY of Lille (CIIL), Lille, France. # and ƒ These authors contriButed equallY to this work. ‡ These authors directed this work *Correspondence to: [email protected] and [email protected] Short title: Covid-19: the hypothalamic hypothesis 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • The Genetic Basis of Human Brain Structure and Function
    bioRxiv preprint doi: https://doi.org/10.1101/178806; this version posted August 21, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The genetic basis of human brain structure and function: 1,262 genome-wide associations found from 3,144 GWAS of multimodal brain imaging phenotypes from 9,707 UK Biobank participants Lloyd T. Elliott1, Kevin Sharp1, Fidel Alfaro-Almagro2, Gwenaëlle Douaud2, Karla Miller2, Jonathan Marchini1,3†‡, Stephen Smith2†‡ 1 Department of Statistics, University of Oxford, Oxford, UK. 2 FMRIB, Wellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK. 3 The Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. † These authors jointly directed this work. ‡ Correspondence to: [email protected], [email protected] The most merciful thing in the world, I think, is the inability of the human mind to correlate all its contents. (H.P. Lovecraft, 1890-1937) bioRxiv preprint doi: https://doi.org/10.1101/178806; this version posted August 21, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract The genetic basis of brain structure and function is largely unknown. We carried out genome-wide association studies (GWAS) of 3,144 distinct functional and structural brain imaging derived phenotypes (IDPs), using imaging and genetic data from a total of 9,707 participants in UK Biobank.
    [Show full text]
  • Us 2018 / 0305689 A1
    US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e .
    [Show full text]
  • Online Supporting Information S2: Proteins in Each Negative Pathway
    Online Supporting Information S2: Proteins in each negative pathway Index Proteins ADO,ACTA1,DEGS2,EPHA3,EPHB4,EPHX2,EPOR,EREG,FTH1,GAD1,HTR6, IGF1R,KIR2DL4,NCR3,NME7,NOTCH1,OR10S1,OR2T33,OR56B4,OR7A10, Negative_1 OR8G1,PDGFC,PLCZ1,PROC,PRPS2,PTAFR,SGPP2,STMN1,VDAC3,ATP6V0 A1,MAPKAPK2 DCC,IDS,VTN,ACTN2,AKR1B10,CACNA1A,CHIA,DAAM2,FUT5,GCLM,GNAZ Negative_2 ,ITPA,NEU4,NTF3,OR10A3,PAPSS1,PARD3,PLOD1,RGS3,SCLY,SHC1,TN FRSF4,TP53 Negative_3 DAO,CACNA1D,HMGCS2,LAMB4,OR56A3,PRKCQ,SLC25A5 IL5,LHB,PGD,ADCY3,ALDH1A3,ATP13A2,BUB3,CD244,CYFIP2,EPHX2,F CER1G,FGD1,FGF4,FZD9,HSD17B7,IL6R,ITGAV,LEFTY1,LIPG,MAN1C1, Negative_4 MPDZ,PGM1,PGM3,PIGM,PLD1,PPP3CC,TBXAS1,TKTL2,TPH2,YWHAQ,PPP 1R12A HK2,MOS,TKT,TNN,B3GALT4,B3GAT3,CASP7,CDH1,CYFIP1,EFNA5,EXTL 1,FCGR3B,FGF20,GSTA5,GUK1,HSD3B7,ITGB4,MCM6,MYH3,NOD1,OR10H Negative_5 1,OR1C1,OR1E1,OR4C11,OR56A3,PPA1,PRKAA1,PRKAB2,RDH5,SLC27A1 ,SLC2A4,SMPD2,STK36,THBS1,SERPINC1 TNR,ATP5A1,CNGB1,CX3CL1,DEGS1,DNMT3B,EFNB2,FMO2,GUCY1B3,JAG Negative_6 2,LARS2,NUMB,PCCB,PGAM1,PLA2G1B,PLOD2,PRDX6,PRPS1,RFXANK FER,MVD,PAH,ACTC1,ADCY4,ADCY8,CBR3,CLDN16,CPT1A,DDOST,DDX56 ,DKK1,EFNB1,EPHA8,FCGR3A,GLS2,GSTM1,GZMB,HADHA,IL13RA2,KIR2 Negative_7 DS4,KLRK1,LAMB4,LGMN,MAGI1,NUDT2,OR13A1,OR1I1,OR4D11,OR4X2, OR6K2,OR8B4,OXCT1,PIK3R4,PPM1A,PRKAG3,SELP,SPHK2,SUCLG1,TAS 1R2,TAS1R3,THY1,TUBA1C,ZIC2,AASDHPPT,SERPIND1 MTR,ACAT2,ADCY2,ATP5D,BMPR1A,CACNA1E,CD38,CYP2A7,DDIT4,EXTL Negative_8 1,FCER1G,FGD3,FZD5,ITGAM,MAPK8,NR4A1,OR10V1,OR4F17,OR52D1,O R8J3,PLD1,PPA1,PSEN2,SKP1,TACR3,VNN1,CTNNBIP1 APAF1,APOA1,CARD11,CCDC6,CSF3R,CYP4F2,DAPK1,FLOT1,GSTM1,IL2
    [Show full text]
  • Supplementary Methods
    doi: 10.1038/nature06162 SUPPLEMENTARY INFORMATION Supplementary Methods Cloning of human odorant receptors 423 human odorant receptors were cloned with sequence information from The Olfactory Receptor Database (http://senselab.med.yale.edu/senselab/ORDB/default.asp). Of these, 335 were predicted to encode functional receptors, 45 were predicted to encode pseudogenes, 29 were putative variant pairs of the same genes, and 14 were duplicates. We adopted the nomenclature proposed by Doron Lancet 1. OR7D4 and the six intact odorant receptor genes in the OR7D4 gene cluster (OR1M1, OR7G2, OR7G1, OR7G3, OR7D2, and OR7E24) were used for functional analyses. SNPs in these odorant receptors were identified from the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP) or through genotyping. OR7D4 single nucleotide variants were generated by cloning the reference sequence from a subject or by inducing polymorphic SNPs by site-directed mutagenesis using overlap extension PCR. Single nucleotide and frameshift variants for the six intact odorant receptors in the same gene cluster as OR7D4 were generated by cloning the respective genes from the genomic DNA of each subject. The chimpanzee OR7D4 orthologue was amplified from chimpanzee genomic DNA (Coriell Cell Repositories). Odorant receptors that contain the first 20 amino acids of human rhodopsin tag 2 in pCI (Promega) were expressed in the Hana3A cell line along with a short form of mRTP1 called RTP1S, (M37 to the C-terminal end), which enhances functional expression of the odorant receptors 3. For experiments with untagged odorant receptors, OR7D4 RT and S84N variants without the Rho tag were cloned into pCI.
    [Show full text]
  • Research/0018.1
    http://genomebiology.com/2001/2/6/research/0018.1 Research The human olfactory receptor repertoire comment Sergey Zozulya, ernando Echeverri and Trieu Nguyen Address: Senomyx Inc., 11099 North Torrey Pines Road, La Jolla, CA 92037, USA. Correspondence: Sergey Zozulya. E-mail: [email protected] reviews Published: 1 June 2001 Received: 8 March 2001 Revised: 12 April 2001 Genome Biology 2001, 2(6):research0018.1–0018.12 Accepted: 18 April 2001 The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2001/2/6/research/0018 © 2001 Zozulya et al., licensee BioMed Central Ltd (Print ISSN 1465-6906; Online ISSN 1465-6914) reports Abstract Background: The mammalian olfactory apparatus is able to recognize and distinguish thousands of structurally diverse volatile chemicals. This chemosensory function is mediated by a very large family of seven-transmembrane olfactory (odorant) receptors encoded by approximately 1,000 genes, the majority of which are believed to be pseudogenes in humans. deposited research Results: The strategy of our sequence database mining for full-length, functional candidate odorant receptor genes was based on the high overall sequence similarity and presence of a number of conserved sequence motifs in all known mammalian odorant receptors as well as the absence of introns in their coding sequences. We report here the identification and physical cloning of 347 putative human full-length odorant receptor genes. Comparative sequence analysis of the predicted gene products allowed us to identify and define a number of consensus sequence motifs and structural features of this vast family of receptors.
    [Show full text]